Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.
High dose thiamine improves fatigue in multiple sclerosis.
Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Confounding in association studies: month of birth and multiple sclerosis.
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
Parent-of-origin effect in multiple sclerosis: observations in half-siblings.
Demyelination: the role of reactive oxygen and nitrogen species.
Self-perceived performance and satisfaction with performance of daily activities in persons with multiple sclerosis following interdisciplinary rehabilitation.
Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis.
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
Yield of emergent neuroimaging among children presenting with a first complex febrile seizure.
The extent of ultrastructural spinal cord pathology reflects disease severity in experimental autoimmune encephalomyelitis.
Gait variability measures reveal differences between multiple sclerosis patients and healthy controls.
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis.
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 mg GA Depot in Subjects With RRMS
Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta.
Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphyz.
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Genmab announces details of planned ofatumumab Phase II study in multiple sclerosis
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis.

Pages